



2024年3月期 第2四半期 決算参考資料  
Financial Data for the 2nd quarter of FY2024  
The FY2024, the year ending March 31, 2024  
April 1, 2023 - March 31, 2024

1. 連結決算概要 / Consolidated Financial Summary	2
2. セグメント別情報 / Information by Business Segment	
(1) 医療分野 / Medical Business	3,4,5
ESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division)	
(2) その他 / Others	6
(3) 全社消去 / Corporate Expenses	6
(4) 非継続事業（科学事業） / Discontinued Operation (Scientific Solutions Business)	6
3. 連結財政状態計算書 / Consolidated Statement of Financial Position	7
4. 連結キャッシュフロー計算書 / Consolidated Statement of Cash Flows	7
5. 会社概要 / Corporate Outline	8

(本資料における留意点について)  
(Notes regarding this material)

- ・本資料のうち、業績見通し等は、現在入手可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が目標と大きく異なる可能性があります。
- ・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利用は、他の方法により入手された情報とも照合確認し、利用者の判断によって行っていただきますようお願い致します。
- ・本資料利用の結果生じたいかなる損害についても、当社は一切責任を負いません。
- ・科学事業の譲渡に関する正式契約の締結に伴い、2023年3月期第2四半期連結会計期間より、科学事業を非継続事業に分類しています。これに伴い、過去に開示した以下の数値も組み替えて表示しています。  
連結損益計算書：「2023年3月期第1四半期（3カ月）」  
連結キャッシュフロー計算書：「2023年3月期第1四半期（3カ月）」
- ・2023年4月に非継続事業（エビデント）の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益を2024年3月期第1四半期連結会計期間に計上しています。
- ・This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
- ・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
- ・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.
- ・Following the conclusion of definitive agreement for divestiture of Scientific Solutions Business, Scientific Solutions Business is categorized as a discontinued operation, effective Q2 of FY2023. Accordingly, figures for below accounting periods are restated.  
Consolidated Statements of Profit or Loss: FY2023.Q1 (3M)  
Consolidated Statement of cash flows: FY2023.Q1 (3M)
- ・Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024.Q1.

1. 連結決算概要 / Consolidated Financial Summary

■ 連結損益計算書概要 / Summary of Consolidated Statements of Profit or Loss

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	As of Aug 9
売上高 Revenue	192,265	224,795	417,060	224,485	240,378	881,923	207,723	228,921	436,644	958,000	914,000
売上原価 Cost of sales	66,544	72,990	139,534	68,287	77,253	285,074	70,497	77,710	148,207	308,000	287,000
売上総利益 Gross profit	125,721	151,805	277,526	156,198	163,125	596,849	137,226	151,211	288,437	650,000	627,000
販売費及び一般管理費 S.G.A. expenses	96,018	102,517	198,535	107,550	114,462	420,547	108,770	112,863	221,633	476,000	446,000
その他の収益および費用等 Other income and expenses etc.	14,818	-206	14,612	321	-4,626	10,307	-5,980	-56,035	-62,015	-74,000	-18,000
営業利益 Operating profit	44,521	49,082	93,603	48,969	44,037	186,609	22,476	-17,687	4,789	100,000	163,000
調整後営業利益 Adjusted operating profit	29,740	49,622	79,362	48,767	48,664	176,793	28,267	38,303	66,570	174,500	182,000
金融収益および費用 Finance income and costs	-2,473	-1,809	-4,282	1,080	-1,113	-4,315	-2,766	-2,981	-5,747	-8,000	-4,000
税引前利益 Profit before tax	42,048	47,273	89,321	50,049	42,924	182,294	19,710	-20,668	-958	92,000	159,000
法人所得税費用 Income taxes	14,158	5,637	19,795	13,956	10,553	44,304	6,224	4,308	10,532	31,000	44,000
継続事業からの当期利益 Profit from continuing operations	27,890	41,636	69,526	36,093	32,371	137,990	13,486	-24,976	-11,490	61,000	115,000
非継続事業からの当期利益(損失) Profit (loss) from discontinued operation	-2,968	382	-2,586	5,336	2,873	5,623	227,128	1,021	228,149	228,000	221,000
当期利益(損失) Profit (loss)	24,922	42,018	66,940	41,429	35,244	143,613	240,614	-23,955	216,659	289,000	336,000
親会社の所有者に帰属する当期利益(損失) Profit (loss) attributable to owners of parent	24,860	41,976	66,836	41,381	35,215	143,432	240,560	-24,264	216,296	289,000	336,000
売上総利益率 Gross profit ratio	65.4%	67.5%	66.5%	69.6%	67.9%	67.7%	66.1%	66.1%	66.1%	67.8%	68.6%
販管費率 S.G.A. ratio	49.9%	45.6%	47.6%	47.9%	47.6%	47.7%	52.4%	49.3%	50.8%	49.7%	48.8%
営業利益率 Operating profit margin	23.2%	21.8%	22.4%	21.8%	18.3%	21.2%	10.8%	-	1.1%	10.4%	17.8%
調整後営業利益率 Adjusted operating margin	15.5%	22.1%	19.0%	21.7%	20.2%	20.1%	13.6%	16.7%	15.2%	18.2%	19.9%
継続事業からの当期利益率 Profit from continuing operations margin	14.5%	18.5%	16.7%	16.1%	13.5%	15.7%	6.5%	-	-	6.4%	12.6%
EBITDA	60,287	65,899	126,186	65,493	58,522	250,201	39,089	-1,406	37,683	166,000	225,000
EBITDAマージン EBITDA margin	31.4%	29.3%	30.3%	29.2%	24.3%	28.4%	18.8%	-	8.6%	17.3%	24.6%

\* FY2023Q2より科学事業を非継続事業に分類しています。非継続事業からの利益は継続事業と区分し、「売上高」から「継続事業からの当期利益」までは継続事業の金額を表示しています。  
From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operations. From "revenue" to "profit from continuing operations" in the above table are amounts related to continuing operations only.

\*2023年4月に非継続事業（エビデント）の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益をFY2024Q1に計上しています。  
Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.

■ 投資他 / Expenditures etc

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	As of Aug 9
減価償却費 Depreciation and amortization	15,766	16,817	32,583	16,524	14,485	63,592	16,613	16,281	32,894	66,000	62,000
資本的支出 Capital expenditures	11,429	18,066	29,495	19,409	23,119	72,023	18,864	15,351	34,215	78,000	68,000
研究開発支出 R&D expenditures	16,965	19,127	36,092	15,333	25,441	76,866	15,356	19,690	35,046	83,000	83,000
開発費資産化 Capitalization of R&D expenditures	1,655	3,908	5,563	3,268	3,748	12,579	2,656	3,575	6,231	16,000	16,000

\* 上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

■ 為替 / Foreign exchange

項目 Item	FY2023						FY2024				FY2024
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	As of Aug 9
円/USD (期中平均レート) Yen/U.S. dollar (Average rate)	129.57	138.37	133.97	141.59	132.34	135.47	137.37	144.62	141.00	145.00	132.00
円/EUR (期中平均レート) Yen/Euro (Average rate)	138.12	139.34	138.73	144.30	142.10	140.97	149.47	157.30	153.39	155.19	144.00
円/CNY (期中平均レート) Yen/Renminyuan (Average rate)	19.58	20.19	19.88	19.87	19.34	19.75	19.56	19.94	19.75	20.07	19.20

売上高に対する為替影響額 FX Impact on revenue	19,482	30,228	49,710	29,050	19,621	98,381	8,278	9,609	17,887	-	-
営業利益に対する為替影響額 FX Impact on operating profit	7,934	13,168	21,102	12,989	10,254	44,345	4,548	-1,125	3,423	-	-

\* 上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

■ 為替感応度 (年間) / Foreign exchange sensitivity (Annual basis) 億円 (¥ 100 million)

項目 Item	売上高 Revenue	営業利益 Operating profit
ドル (1円あたり) U.S. dollar (Per 1JPY)	25	7
ユーロ (1円あたり) Euro (Per 1JPY)	16	6
人民元 (1円あたり) Renminyuan (Per 1JPY)	58	35

\* 上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

\* 上表の数値はFY2023Q4実績より算出しています。 / Amounts in the above table are calculated based on FY2023Q4 results.

\* Veran Medical Technologies社製品の製造・販売終了に関する損失がドル建てで計上されており、FY2024のドル建ての利益がFY2023よりも減少する見込みであることから、FY2024の営業利益に対するドルの為替感応度は約3億円となる見込みです。 / The losses associated with the discontinuation of manufacture and sale of products from Veran Medical Technologies, Inc. is originally recorded in US dollar. Considering that the profit in US dollars in FY2024 is expected to be lower than in FY2023 due to the losses, the foreign exchange sensitivity of the US dollar to operating profit in FY2024 is expected to be about ¥300 million.

2. セグメント別情報 / Information by Business Segment

(1) 医療分野 / Medical Business

■ ESD 損益 / Revenue and Operating profit of ESD

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024 As of Aug 9
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	
売上高 Revenue	116,857	141,615	258,472	140,518	152,833	551,823	127,138	143,729	270,867	604,000	572,000
営業利益 Operating profit	24,834	44,065	68,899	41,804	42,066	152,769	22,177	28,732	50,909	150,000	158,000
その他の損益 Other income and expenses	-1,179	-236	-1,415	-908	-1,503	-3,826	-3,390	-4,423	-7,813	-13,000	-10,000
調整後営業利益 Adjusted operating profit	26,013	44,301	70,314	42,712	43,569	156,595	25,567	33,155	58,722	163,000	168,000
営業利益率 Operating profit margin	21.3%	31.1%	26.7%	29.7%	27.5%	27.7%	17.4%	20.0%	18.8%	24.8%	27.6%
調整後営業利益率 Adjusted operating margin	22.3%	31.3%	27.2%	30.4%	28.5%	28.4%	20.1%	23.1%	21.7%	27.0%	29.4%
売上高対前年比 Revenue (YoY)	-	-	-	-	-	-	8.8%	1.5%	4.8%	9.5%	-
営業利益対前年比 Operating profit (YoY)	-	-	-	-	-	-	-10.7%	-34.8%	-26.1%	-1.8%	-

■ TSD 損益 / Revenue and Operating profit of TSD

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024 As of Aug 9
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	
売上高 Revenue	72,365	80,570	152,935	81,007	84,265	318,207	77,156	82,542	159,698	342,000	329,000
営業損益 Operating profit (loss)	13,357	16,431	29,788	18,328	15,576	63,692	9,681	-38,223	-28,542	-4,500	56,000
その他の損益 Other income and expenses	-242	116	-126	1,288	-1,751	-589	-1,899	-52,765	-54,664	-59,000	-7,000
調整後営業利益 Adjusted operating profit	13,599	16,315	29,914	17,040	17,327	64,281	11,580	14,542	26,122	54,500	63,000
営業利益率 Operating profit margin	18.5%	20.4%	19.5%	22.6%	18.5%	20.0%	12.5%	-	-	-	17.0%
調整後営業利益率 Adjusted operating margin	18.8%	20.2%	19.6%	21.0%	20.6%	20.2%	15.0%	17.6%	16.4%	15.9%	19.1%
売上高対前年比 Revenue (YoY)	-	-	-	-	-	-	6.6%	2.4%	4.4%	7.5%	-
営業利益対前年比 Operating profit (YoY)	-	-	-	-	-	-	-27.5%	-	-	-	-

■ 医療分野 損益 / Revenue and Operating profit of Medical Business

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024 As of Aug 9
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	
売上高 Revenue	189,222	222,185	411,407	221,525	237,098	870,030	204,294	226,271	430,565	946,000	901,000
営業利益 Operating profit	38,191	60,496	98,687	60,132	57,642	216,461	31,858	-9,491	22,367	145,500	214,000
その他の損益 Other income and expenses	-1,421	-120	-1,541	380	-3,254	-4,415	-5,289	-57,188	-62,477	-72,000	-17,000
調整後営業利益 Adjusted operating profit	39,612	60,616	100,228	59,752	60,896	220,876	37,147	47,697	84,844	217,500	231,000
営業利益率 Operating profit margin	20.2%	27.2%	24.0%	27.1%	24.3%	24.9%	15.6%	-	5.2%	15.4%	23.8%
調整後営業利益率 Adjusted operating margin	20.9%	27.3%	24.4%	27.0%	25.7%	25.4%	18.2%	21.1%	19.7%	23.0%	25.6%
売上高対前年比 Revenue (YoY)	-	-	-	-	-	-	8.0%	1.8%	4.7%	8.7%	-
営業利益対前年比 Operating profit (YoY)	-	-	-	-	-	-	-16.6%	-	-77.3%	-	-

■ ESD 投資他 / Expenditures etc of ESD

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
減価償却費 Depreciation and amortization	9,167	9,947	19,114	10,157	8,224	37,495	10,276	10,261	20,537
資本的支出 Capital expenditures	6,749	11,393	18,142	11,996	12,863	43,001	11,821	10,196	22,017
研究開発支出 R&D expenditures	8,861	10,800	19,661	8,498	16,114	44,273	9,596	12,565	22,161

■ TSD 投資他 / Expenditures etc of TSD

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
減価償却費 Depreciation and amortization	4,793	4,846	9,639	4,874	4,646	19,159	4,683	4,551	9,234
資本的支出 Capital expenditures	3,119	3,355	6,474	3,849	5,531	15,854	3,721	4,373	8,094
研究開発支出 R&D expenditures	5,198	5,502	10,700	4,722	7,303	22,725	3,730	5,269	8,999

■ 医療分野 投資他 / Expenditures etc of Medical Business

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
減価償却費 Depreciation and amortization	13,960	14,793	28,753	15,031	12,870	56,654	14,959	14,812	29,771
資本的支出 Capital expenditures	9,868	14,748	24,616	15,845	18,394	58,855	15,542	14,569	30,111
研究開発支出 R&D expenditures	14,059	16,302	30,361	13,220	23,417	66,998	13,326	17,834	31,160

■ ESD 地域別売上高 / Revenue by Region of ESD

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
日本 Japan	14,914	18,059	32,973	15,318	22,181	70,472	16,142	18,589	34,730
北米 North America	44,432	50,948	95,380	50,854	51,900	198,134	45,822	50,968	96,790
欧州 Europe	30,993	31,034	62,028	34,968	37,312	134,307	31,070	31,581	62,651
中国 China	12,388	24,100	36,488	22,625	23,793	82,906	17,415	23,391	40,806
アジア・オセアニア Asia and Oceania	11,195	13,448	24,643	13,186	14,062	51,891	13,389	14,899	28,288
その他 Others	2,935	4,026	6,960	3,567	3,585	14,113	3,300	4,302	7,602
合計 Total	116,857	141,615	258,472	140,518	152,833	551,823	127,138	143,730	270,867

■ TSD 地域別売上高 / Revenue by Region of TSD

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
日本 Japan	10,781	11,654	22,435	11,698	12,037	46,170	10,925	10,988	21,913
北米 North America	28,654	31,575	60,229	32,173	31,472	123,874	30,351	32,892	63,243
欧州 Europe	19,261	18,830	38,091	21,708	22,612	82,411	20,498	20,516	41,014
中国 China	6,836	10,160	16,996	7,451	9,700	34,147	7,010	8,935	15,945
アジア・オセアニア Asia and Oceania	5,469	6,832	12,301	6,513	6,729	25,543	6,805	7,355	14,160
その他 Others	1,364	1,519	2,883	1,464	1,715	6,062	1,567	1,856	3,423
合計 Total	72,365	80,570	152,935	81,007	84,265	318,207	77,156	82,542	159,698

■ 医療分野 地域別売上高 / Revenue by Region of Medical Business

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
日本 Japan	25,695	29,713	55,408	27,016	34,218	116,642	27,067	29,577	56,643
北米 North America	73,086	82,523	155,609	83,027	83,372	322,008	76,173	83,860	160,033
欧州 Europe	50,254	49,864	100,119	56,676	59,924	216,718	51,568	52,097	103,665
中国 China	19,224	34,260	53,484	30,076	33,493	117,053	24,425	32,326	56,751
アジア・オセアニア Asia and Oceania	16,664	20,280	36,944	19,699	20,791	77,434	20,194	22,254	42,448
その他 Others	4,299	5,545	9,843	5,031	5,300	20,175	4,867	6,158	11,025
合計 Total	189,222	222,185	411,407	221,525	237,098	870,030	204,294	226,272	430,565

■ ESDサブセグメント別売上占有率 / Sub-segment Sales Ratio within ESD

(FY2024 Q2 Total)

消化器内視鏡 Gastrointestinal Endoscope	外科内視鏡 Surgical Endoscope	医療サービス Medical Service
約 Approx. 55%	約 Approx. 10%	約 Approx. 35%

■ TSDサブセグメント別売上占有率 / Sub-segment Sales Ratio within TSD

(FY2024 Q2 Total)

消化器科 (処置具) GI-Endotherapy	泌尿器科 Urology	呼吸器科 Respiratory	その他の治療領域 Other Therapeutic Areas
約 Approx. 30%	約 Approx. 35%	約 Approx. 15%	約 Approx. 20%

\* 四捨五入のため、合計値が100%にならないことがあります。 / Due to rounding, the total may not add up to 100%.

■地域別成長率（為替影響調整後） /

Growth Rate by Region (After Foreign Exchange Adjustment)

項目 Item		FY2023						FY2024			
		Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	
ESD	日本 Japan	10% (10%)	2% (2%)	5% (5%)	-2% (-2%)	16% (16%)	7% (7%)	8% (8%)	3% (3%)	5% (5%)	
	北米 North America	19% (0%)	29% (3%)	24% (2%)	32% (7%)	13% (-1%)	23% (2%)	3% (-3%)	0% (-4%)	1% (-3%)	
	欧州 Europe	24% (14%)	5% (-6%)	14% (3%)	12% (-1%)	19% (10%)	15% (4%)	0% (-6%)	2% (-7%)	1% (-7%)	
	中国 China	-10% (-23%)	14% (-4%)	5% (-12%)	57% (38%)	25% (15%)	21% (6%)	41% (40%)	-3% (-2%)	12% (12%)	
	アジア・オセアニア Asia and Oceania	30% (21%)	29% (16%)	30% (19%)	26% (14%)	38% (28%)	31% (20%)	20% (18%)	11% (7%)	15% (12%)	
	分野計 Total	17% (5%)	17% (1%)	17% (3%)	24% (8%)	20% (10%)	20% (6%)	9% (5%)	1% (-3%)	5% (1%)	
	TSD	日本 Japan	6% (6%)	-2% (-2%)	1% (1%)	-1% (-1%)	10% (10%)	3% (3%)	1% (1%)	-6% (-6%)	-2% (-2%)
		北米 North America	20% (1%)	25% (0%)	23% (1%)	28% (3%)	22% (7%)	24% (3%)	6% (0%)	4% (0%)	5% (0%)
欧州 Europe		16% (9%)	16% (5%)	16% (7%)	8% (-4%)	14% (5%)	13% (3%)	6% (-1%)	9% (-2%)	8% (-1%)	
中国 China		-2% (-16%)	4% (-13%)	2% (-14%)	11% (-3%)	6% (-2%)	5% (-9%)	3% (2%)	-12% (-11%)	-6% (-6%)	
アジア・オセアニア Asia and Oceania		5% (-2%)	30% (18%)	18% (8%)	18% (8%)	30% (21%)	21% (11%)	24% (23%)	8% (4%)	15% (12%)	
分野計 Total		14% (2%)	16% (1%)	15% (1%)	15% (0%)	17% (7%)	15% (3%)	7% (2%)	2% (-2%)	4% (0%)	
医療分野 Medical Business		日本 Japan	8% (8%)	0% (0%)	4% (4%)	-2% (-2%)	14% (14%)	5% (5%)	5% (5%)	0% (0%)	2% (2%)
		北米 North America	19% (1%)	28% (2%)	24% (1%)	30% (5%)	16% (2%)	23% (2%)	4% (-1%)	2% (-3%)	3% (-2%)
	欧州 Europe	21% (12%)	9% (-2%)	15% (5%)	10% (-2%)	17% (8%)	14% (4%)	3% (-4%)	4% (-5%)	4% (-4%)	
	中国 China	-7% (-20%)	11% (-7%)	4% (-12%)	42% (25%)	19% (10%)	16% (2%)	27% (27%)	-6% (-5%)	6% (6%)	
	アジア・オセアニア Asia and Oceania	21% (12%)	30% (17%)	26% (15%)	23% (12%)	35% (25%)	27% (17%)	21% (19%)	10% (6%)	15% (12%)	
	分野計 Total	16% (4%)	17% (1%)	16% (2%)	21% (5%)	19% (9%)	18% (5%)	8% (4%)	2% (-2%)	5% (0%)	

\* ( ) は為替影響調整後の成長率です。 / ( ) :Growth rate after foreign exchange adjustment

■サブセグメント別成長率（為替影響調整後） /

Growth Rate by Sub-segment (After Foreign Exchange Adjustment)

項目 Item		FY2023						FY2024		
		Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
ESD	消化器内視鏡 Gastrointestinal Endoscope	18% (5%)	17% (1%)	17% (3%)	27% (10%)	19% (9%)	20% (6%)	3% (0%)	-5% (-8%)	-1% (-5%)
	外科内視鏡 Surgical Endoscope	11% (-1%)	4% (-10%)	7% (-6%)	7% (-7%)	33% (22%)	14% (2%)	24% (19%)	-2% (-5%)	9% (6%)
	医療サービス Medical Service	17% (5%)	25% (8%)	21% (7%)	27% (10%)	15% (5%)	21% (7%)	13% (8%)	14% (8%)	14% (8%)
	分野計 Total	17% (5%)	17% (1%)	17% (3%)	24% (8%)	20% (10%)	20% (6%)	9% (5%)	1% (-3%)	5% (1%)
	TSD	消化器科（処置具） GI-Endotherapy	14% (5%)	15% (3%)	14% (4%)	12% (2%)	17% (9%)	14% (5%)	9% (5%)	11% (6%)
泌尿器科 Urology		18% (4%)	24% (4%)	21% (4%)	22% (3%)	22% (10%)	22% (6%)	8% (2%)	1% (-4%)	4% (-1%)
呼吸器科 Respiratory		7% (-5%)	9% (-7%)	8% (-7%)	14% (-2%)	11% (2%)	10% (-3%)	2% (-2%)	2% (-2%)	2% (-2%)
その他の治療領域 Other Therapeutic Areas		12% (2%)	12% (-1%)	12% (0%)	8% (-5%)	16% (7%)	12% (1%)	5% (1%)	-5% (-9%)	0% (-4%)
分野計 Total		14% (2%)	16% (1%)	15% (1%)	15% (0%)	17% (7%)	15% (3%)	7% (2%)	2% (-2%)	4% (0%)

\* ( ) は為替影響調整後の成長率です。 / ( ) :Growth rate after foreign exchange adjustment

## 2. セグメント別情報 / Information by Business Segment

### (2) その他 / Others

#### ■ 損益 / Revenue and Operating profit

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	As of Aug 9
売上高 Revenue	3,043	2,610	5,653	2,960	3,280	11,893	3,429	2,650	6,079	12,000	13,000
営業損益 Operating profit (loss)	-296	-492	-788	-129	3	-914	-141	1,141	1,000	1,000	1,000
その他の損益 Other income and expenses	0	-8	-8	-26	6	-28	-144	1,154	1,010	1,000	1,000
営業利益率 Operating profit margin	-	-	-	-	-	-	-	43.1%	16.5%	8.3%	

売上高対前年比 Revenue (YoY)	/	/	/	/	/	/	12.7%	1.5%	7.5%	0.9%
営業利益対前年比 Operating profit (YoY)	/	/	/	/	/	/	-	-	-	-

\* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

#### ■ 地域別売上高 / Revenue by Region

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
日本 Japan	1,603	1,364	2,967	1,357	1,550	5,874	1,511	1,300	2,812
北米 North America	40	34	74	30	55	159	67	15	82
欧州 Europe	1,321	1,103	2,424	1,419	1,603	5,446	1,421	1,295	2,716
中国 China	7	14	21	10	10	41	310	7	317
アジア・オセアニア Asia and Oceania	72	95	167	144	62	373	120	32	152
その他 Others	-	-	-	-	-	-	-	-	-
合計 Total	3,043	2,610	5,653	2,960	3,280	11,893	3,429	2,649	6,079

\* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

### (3) 全社消去 / Corporate expenses

#### ■ 損益 / Revenue and Operating profit

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	As of Aug 9
売上高 Revenue	-	-	-	-	-	-	-	-	-	-	-
営業損益 Operating profit (loss)	6,626	-10,922	-4,296	-11,034	-13,608	-28,938	-9,241	-9,337	-18,578	-46,500	-52,000
その他の損益 Other income and expenses	16,202	-412	15,790	-152	-1,379	14,259	-358	44	-314	-3,500	-3,000

\* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

#### ■ 投資他 (その他・全社消去) / Expenditures etc (Others, Corporate expenses)

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
減価償却費 Depreciation and amortization	1,806	2,024	3,830	1,493	1,615	6,938	1,654	1,469	3,123
資本的支出 Capital expenditures	1,561	3,318	4,879	3,564	4,725	13,168	3,322	782	4,104
研究開発支出 R&D expenditures	2,906	2,825	5,731	2,113	2,024	9,868	2,030	1,856	3,886

\* FY2023Q2より科学事業を非継続事業に分類したことに伴い、減価償却費及び資本的支出のFY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation.

Accordingly, we restated figures for "depreciation and amortization" and "capital expenditures" for FY2023Q1.

### (4) 非継続事業 (科学事業) / Discontinued Operation (Scientific Solutions Business)

#### ■ 損益 / Revenue and Operating profit

百万円 (¥ million)

項目 Item	FY2023						FY2024				FY2024
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total	Total forecast	As of Aug 9
売上高 Revenue	21,795	30,949	52,744	38,267	44,410	135,421	-	-	-	-	-
営業損益 Operating profit (loss)	-3,745	-1,138	-4,883	6,364	5,554	7,035	347,628	554	348,182	348,000	347,000
その他の損益 Other income and expenses	-2,336	-2,609	-4,945	-3,309	-2,726	-10,980	348,125	445	348,570	348,500	347,500
営業利益率 Operating profit margin	-	-	-	16.6%	12.5%	5.2%	-	-	-	-	-

\* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

\* 2023年4月に非継続事業 (エビデント) の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益をFY2024Q1に計上しています。

Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.

3. 連結財政状態計算書 / Consolidated statement of financial position

百万円 (¥ million)

項目 Item	FY2023				FY2024			
	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31
資産 Assets	1,433,466	1,486,123	1,392,608	1,508,308	1,688,272	1,617,765	-	-
流動資産 Current assets	723,090	791,579	722,541	726,357	964,843	921,789	-	-
現金及び現金同等物 Cash and cash equivalents	286,412	255,765	175,748	169,329	558,722	488,160	-	-
棚卸資産 Inventories	186,875	171,182	170,912	162,994	177,487	183,430	-	-
売却目的で保有する資産 Assets held for sale	-	122,512	132,273	169,621	565	-	-	-
その他 Others	249,803	242,120	243,608	224,413	228,069	250,199	-	-
非流動資産 Non-current assets	710,376	694,544	670,067	781,951	723,429	695,976	-	-
負債 Liabilities	851,311	842,027	787,020	867,074	781,348	790,233	-	-
流動負債 Current liabilities	362,857	359,737	355,252	461,892	416,394	423,282	-	-
売却目的で保有する資産に直接関連する負債 Liabilities directly associated with assets held for sale	-	34,404	32,799	43,253	28	-	-	-
非流動負債 Non-current liabilities	488,454	482,290	431,768	405,182	364,954	366,951	-	-
資本 Equity	582,155	644,096	605,588	641,234	906,924	827,532	-	-
親会社の所有者に帰属する持分 Total equity attributable to owners of parent	581,125	643,024	604,468	640,085	905,904	827,532	-	-
その他 Others	1,030	1,072	1,120	1,149	1,020	-	-	-

有利子負債 Interest-bearing debt	394,794	389,798	352,735	340,057	345,966	348,414	-	-
純有利子負債 Net debt	108,382	134,033	176,987	170,728	-212,756	-139,746	-	-
自己資本比率 Equity ratio	40.5%	43.3%	43.4%	42.4%	53.7%	51.2%	-	-
有利子負債比率 Interest-bearing debt ratio	67.9%	60.6%	58.4%	53.1%	38.2%	42.1%	-	-

4. 連結キャッシュ・フロー計算書 / Consolidated statement of cash flows

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
営業キャッシュ・フロー Cash flows from operating activities	-14,001	41,279	27,278	27,665	43,547	98,490	-53,112	41,335	-11,777
投資キャッシュ・フロー Cash flows from investing activities	5,198	-20,851	-15,653	-22,207	-20,554	-58,414	426,988	-14,287	412,701
フリー・キャッシュ・フロー Free cash flow	-8,803	20,428	11,625	5,458	22,993	40,076	373,876	27,048	400,924
調整後フリー・キャッシュ・フロー Adjusted Free cash flow	-7,378	23,557	16,179	26,233	42,893	85,305	-10,266	27,961	17,695
財務キャッシュ・フロー Cash flows from financing activities	-21,748	-13,704	-35,452	-76,982	-30,744	-143,178	-25,888	-99,534	-125,422

\* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。/  
From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

\*調整後フリー・キャッシュ・フローの主な特殊要因はプレゼンテーションを参照ください。/Please refer to the presentation for the major adjusted items of adjusted free cash flow.

\* FY2023Q2の営業キャッシュ・フローに占める一部為替影響の修正に伴い、FY2023Q1、Q2、Q2Total、Q3についても数値を遡及して修正しています。/  
Due to a revision of some foreign exchange effects on cash flows from operating activities in FY2023 Q2, the figures for FY2023Q1,Q2, Q2total, and Q3 have been retroactively revised.

なお、非継続事業からのキャッシュ・フローは以下の通り / Cash flows from discontinued operation are as below.

百万円 (¥ million)

項目 Item	FY2023						FY2024		
	Q1	Q2	Q2 Total	Q3	Q4	Total	Q1	Q2	Q2 Total
営業キャッシュ・フロー Cash flows from operating activities	-9,871	-1,087	-10,958	-2,693	500	-13,151	-57,303	-364	-57,667
投資キャッシュ・フロー Cash flows from investing activities	-4,435	-1,582	-6,017	-2,195	-3,513	-11,725	436,835	-2,937	433,898
財務キャッシュ・フロー Cash flows from financing activities	-416	-623	-1,039	-327	-1,525	-2,891	-	-	-

## 5. 会社概要 / Corporate Outline

### ■会社概要 / Corporate outline

2023年9月30日現在  
As of Sep 30, 2023

会社名 Company name	オリンパス株式会社 Olympus Corporation
上場市場 Market	東京証券取引所プライム市場 Prime Market
銘柄コード Stock code	7733 ISIN: JP3201200007
設立年月日 Established	1919年10月12日 October 12, 1919
資本金（百万円） Capital (¥ million)	124,643
グループ会社数 Number of group companies	92（本社除く / excluding Olympus Corporation） 〒163-0914 東京都新宿区西新宿2丁目3番1号 新宿モリス
本社 Head Office	https://www.olympus.co.jp/ Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japan https://www.olympus-global.com/network/
事業場 Factory, R&D Center	八王子市（東京都）、上伊那郡（長野県）、西白河郡（福島県） Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref.
支店 Branch Offices	札幌、名古屋、大阪、広島、福岡、神戸 Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka, Kobe
営業所 Sales Offices	新潟、松本、静岡、金沢、京都、岡山、松山、鹿児島 Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshima
海外拠点 Overseas Offices	アメリカ、ドイツ、イギリス、中国、シンガポールほか USA, Germany, UK, China, Singapore etc

### ■株式状況 / Stock information

2023年9月30日現在  
As of Sep 30, 2023

発行可能株式総数（株） Total Number of Authorized Shares (Shares)	4,000,000,000
発行済株式総数（株） Number of Shares Issued (Shares)	1,266,178,700

### ■株式の分布状況 / Shareholder Distribution

2023年9月30日現在  
As of Sep 30, 2023

	所有株式数 Number of shares	所有株式数の割合 Shareholders ratio
金融機関 Japanese financial institution	438,263,892	34.6%
証券会社 Japanese securities firms	19,187,079	1.5%
その他国内法人 Other Japanese corporations	27,022,692	2.1%
外国人 Foreign institutions and individuals	660,893,097	52.2%
個人・その他 Jananese individuals and others	76,173,209	6.0%
自己株式 Treasury stock	44,638,731	3.5%
合計 Total	1,266,178,700	100.0%

### ■従業員数 / Number of employees

項目 Item	FY2023		FY2024			
	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31	
合計（非継続事業含む） Total (Including discontinued operation)	32,805 (19,977)	28,527 (17,097)	28,712 (17,335)	-	-	-
内視鏡事業 Endoscopic Solutions Division	14,261 (7,766)	14,583 (7,916)	14,684 (8,045)	-	-	-
治療機器事業 Therapeutic Solutions Division	8,444 (6,042)	8,358 (6,033)	8,455 (6,126)	-	-	-
医療分野 Medical Business	22,705 (13,808)	22,941 (13,949)	23,139 (14,171)	-	-	-
その他、全社 Others, Corporate	5,976 (3,517)	5,586 (3,148)	5,573 (3,164)	-	-	-
非継続事業 Discontinued Operation	4,124 (2652)	0 (0)	0 (0)	-	-	-

\* ( ) は海外従業員数です。 / ( ) : Number of overseas employees

\* FY2024Q1より一部地域で要員数の基準が変更になったことに伴い、FY2023Q4についても数値を遡及して修正しています。 /

Due to a change in the standard for the number of personnel in some regions from FY2024Q1, the figures for FY2023Q4 have been retroactively revised.